The Pathology Core Component supports all of the program projects by providing anatomic and hematopathology data. Beyond the usual activities of a diagnostic pathology service, this component provides special attention to collection of research data which is then available to all investigators in the grant. Pathology also coordinates extensive specimen collection from biopsies and autopsies needed to carry out the research proposals, including preparation of frozen tissues and tissue culture specimens, and support for immunology, virology, and molecular biology through immunohistochemical and DNA hybridization techniques and other histological methods. Research support activities include: 1) extensive autopsies on all autologous marrow transplant recipients, 2) continued studies of lymph node and thymus gland tissue in autologous recipients in comparison to those of allogeneic recipients to further elucidate the differences attributable to allograft defects, 3) continued study of autologous skin rashes for immunobiological mechanisms, particularly by way of protocol 568 and comparison to skin biopsies of patients undergoing treatment with IL-2/LAK, GM-CSF and other cytokines, 4) continued study and development of viral probes and PCR methodology for the study of viral infections, including the development of a 4 virus screen for diagnosis, 5) systematic study of marrow damage correlates for the cytokine studies of Project 14, and 6) continued study of veno-occlusive disease in autologous recipients via liver biopsy, especially transvenous biopsy techniques.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047748-05
Application #
3773358
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Bensinger, W I (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23:442-8
Bensinger, William (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 26:480-92
Bensinger, William I (2007) Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract Res Clin Haematol 20:783-95
Bensinger, William I (2007) Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci 12:4384-92
Zaucha, Renata E; Buckner, Dean C; Barnett, Todd et al. (2006) Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 64:227-34
Bensinger, W I (2006) The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 20:1683-9
Bensinger, William I (2004) The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. J Natl Compr Canc Netw 2:371-8
Bensinger, William I (2004) The current status of hematopoietic stem cell transplantation for multiple myeloma. Clin Adv Hematol Oncol 2:46-52
Yusuf, U; Frangoul, H A; Gooley, T A et al. (2004) Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 33:805-14
Einsele, H; Bamberg, M; Budach, W et al. (2003) A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant 32:593-9

Showing the most recent 10 out of 150 publications